Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Industry News

    Sarepta Marburg Drug Shows Promising Survival Rates

    By Global Biodefense StaffAugust 13, 2012
    Share
    Facebook LinkedIn Reddit Email

    Sarepta Therapeutics – formerly known as AVI BioPharma – has demonstrated unprecedented achievement for their lead therapeutic drug candidate for the Marburg virus, AVI-7288. The effort is funded by the Department of Defense’s (DoD) Joint Program Executive Office for Chemical and Biological Defense, Joint Project Manager Transformational Medical Technologies (JPM-TMT).

    The candidate demonstrated significant survival rates between 83% and 100% in a non-human primate study exploring the drug’s effect when treatment is delayed for up to several days post-infection. The placebo-treated control group had a 0% survival rate.

    “Showing efficacy when used up to four days post infection is a very significant step in the development of the Marburg drug candidate,” noted David E. Hough, Joint Project Manager for JPM-TMT. “Our goal is to protect the Warfighter and the nation from naturally occurring or weaponized viruses and this new development means that we may soon be able to offer treatments for a lethal and fast-acting virus even days after the suspected exposure.”

    Marburg virus is a considered Biosafety Level 4 (BSL 4) priority pathogen, requiring the highest level of containment. Sarepta is working with scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to conduct the studies, which will now monitor the subject non-human primates off-treatment through day 40 to analyze additional indicators such as liver enzymes and renal markers.

    Through its Hemorrhagic Fever Virus-Therapeutics Medical Countermeasures acquisition program (HFV-Tx MCM), JPM-TMT is targeting Marburg as a model for testing the development of rapidly adaptable platform-based, post-exposure therapeutics for other hemorrhagic fever viruses.

    While the success of the Marburg project at Sarepta is significant, recently imposed budget constraints prompted the DoD to issue a stop-work order to the company on August 2, 2012 with respect to the Ebola portion of their contract for Advanced Development of Hemorrhagic Fever Virus Therapeutics.

    The stop-work order does not apply to the Marburg effort funded under the same contract. The stop-work order will remain in effect until September 1, 2012, and prior to that time the DoD will either: (1) terminate the Ebola portion of the contract; (2) cancel the stop-work order; or (3) extend the stop-work order period, if necessary.

    Biosafety Ebola JPEO-CBRND Marburg USAMRIID
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleCritical Reagents Program Issues RFI for Biodefense Material Services
    Next Article West Nile Virus Death Toll Reaches 16 in Texas

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.